NEOGENOMICS, INC. (NEO)

Every figure this model derived for NEO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-03-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 27,508,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-03-31
cash 328,459,000 CashAndCashEquivalentsAtCarryingValue 2026-03-31
current assets 373,684,000 AssetsCurrent 2026-03-31
current liabilities 84,590,000 LiabilitiesCurrent 2026-03-31
equity 828,760,000 StockholdersEquity 2026-03-31
interest expense 2,733,000 InterestExpenseNonoperating 2026-03-31
ocf 22,420,000 NetCashProvidedByUsedInOperatingActivities 2026-03-31
revenue 745,969,000 RevenueFromContractWithCustomerIncludingAssessedTax 2026-03-31
sbc 40,198,000 ShareBasedCompensation 2026-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up NEO on one particular measure came for.

RatioValue
cash operating margin-4.1
current ratio4.45
current ratio reported4.42
deferred revenue growth-51.76
dilution pct1.14
fcf margin-0.68
growth cv0.34
interest cover-38.89
operating margin-14.25
owner earnings margin-6.07
revenue growth10.95
revenue growth per share9.7
roic-9.97
rpo growth27.81
rule of 40-3.3
sbc pct revenue5.39

What to be careful about

What this model itself distrusts about NEO's figures. Written by the derivation as it ran, not added afterwards.